Abstract
It is well known that the vascular smooth muscle tone is regulated not only by the activity of the sympathetic nervous system, but also by the release of vasoactive factors from the endothelium including nitric oxide (NO), prostacyclin, thromboxane A2 and endothelin (1; 2; 3) that can be induced by both chemical and mechanical stimuli (4). In addition, several studies have reported endothelium-independent vasodilator responses to an unknown endogenous mediator, in rabbit and rat resistance arteries (5;6). PAF is a potent phospholipid mediator released by various cell types including platelets, leukocytes, macrophages, endothelial cells (7) and cultured rat vascular smooth muscle cells (8). This mediator has many biological actions already described (9). Several reports have demonstrated that PAF (<1 μg kg−1, i.v.) induce severe cardiovascular alterations, including a decrease in arterial blood pressure (10; 11), a direct negative chronotropic effect (12; 13) and an increase in vascular permeability (14). The hypotensive effect of PAF has been attributed mainly to the dilation of resistance vessels (15;16), thus suggesting a role for this mediator in the modulation of vascular smooth muscle tone.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Furchgott, R.F. (1983). Role of endothelium in response of vascular smooth muscle. Circ. Res., 53, 557–573.
Vane, J. (1993). Control of the circulation by endothelial mediators. Int. Arch. Allergy Immunol., 101, 333–345.
Bevan, J.A. and Henrion, D. (1994). Pharmacological implications of the flow-dependence of vascular smooth muscle tone. Annu. Rev. Pharmacol. Toxicol., 34, 173–190.
Kuo, L.I.H., Chilian, W.H., Davis, M.J. (1991). Interaction of pressure-and flow-induced responses in porcine coronary resistance vessels. Am. J. Physiol., 260, H1706 - H1715.
Gaw, A.J. and Bevan, J.A. (1993). Flow-induced relaxation of the rabbit middle cerebral artery is composed of both endothelium-dependent and -independent components. Stroke, 24, 105–110.
Rees, D.D, Cellek, S., Palmer, R.M.J. and Moncada, S. (1990). Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the effects on vascular tone. An insight into endotoxin shock. Biochem. Biophys. Res. Commun., 173, 541–547.
Cordeiro, R.S.B., Martins, M.a. and Silva, P.M.R. (1988). Proinflammatory activity of platelet-activating factor: pharmacological modulation and cellular involvement. Prog. Biochem. Pharmacol., 22, 156–167.
Tomlinson, P.R., Croft, K., Harris, T. and Stewart, A.G. (1994). Platelet-activating factor biosynthesis in rat vascular smooth muscle cells. J. Vase. Res., 31, 144–152.
Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.B. (1987). Perspectives in platelet-activating factor research. Pharmacol. Rev., 39, 97–145.
Caillard, C.G., Mondot, S., Zundel, J.L. and Julou, L. (1982). Hypotensive activity of PAF-acether in rats. Agents Actions, 12, 725–730.
Felix, S.B., Baumann, G., Raschke, P., Maus, C. and Berdel, W.E. (1990). Cardiovascular reactions and respiratory events during platelet activating factor-induced shock. Basic Res. Cardiol., 85, 217–226.
Sybertz, E.J., Watkins, R.W., Baum, T., Pula, K. and Rivelli, M. (1985). Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. J. Pharmacol. Exp. Ther., 232, 156–162.
Robertson, D.a., Genovese, a. and Levi, R. (1987). Negative inotropic effect of platelet-activating factor in human myocardium: A pharmacological study. J. Pharmacol. Exp. Ther. 243: 834–839.
Macmanus, L.M., Hanahan, D.J., Demopoulos, C.a. and Pinckard, R.N. (1980). Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J. Immunol., 124, 2919–2924.
Blank, M.L., Snyder, F., Byers, L.W., Brooks, B., Muirhead, E.E. (1979). Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem. Biophys. Res. Commun., 90: 1194–1200.
Yamanaka, S., Katsuyuki, M., Yukimura, T., Okumura, M., Yamamoto, K. (1992). Putative mechanisms of hypotensive action of platelet-activating factor in dogs. Circ. Res. 70: 893–901.
Benveniste, J., Henson, P.M. and Cochrane, C.J. (1972). Leukocyte-dependent histamine release from rabbit platelets: The role of IgE basóphils and a platelet-activating factor. J. Exp. Med., 136, 1356–1377.
Braquet, P. and Hosford, D. (1991). Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. Ethnopharmacol., 32, 135–139.
Casals-Stenzel, J., Muacevic, G. and Weber, K.-H. (1987). Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J. Pharmacol. Exp. Ther., 241, 974–981.
Castro-Faria-Neto, H.C., Araújo, C.V., Moreira, S., Bozza, P.T., Thomas, G., Barbosa-Filho, J.M., Cordeiro, R.S.B. and Tibiriçâ, E. (1995): Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies. Planta Medica, 61, 106–112.
Vargaftig, B.B. and Hai, N.D. (1972). Selective inhibition by mepacrine of the release of “rabbit aorta contracting substance” evoked by the administration of bradykinin. J. Pharm. Pharmacol., 24, 159–161.
Blackwell, G.J., Duncombe, W.G., Flower, R.J., Parsons, M.F. and Vane, J.R. (1977). The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br. J. Pharmacol., 59, 353–366.
Henson, P., Barnes, P. and Banks-Schlegel, S.P. (1992). Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities. Am. Rev. Respir. Dis., 145, 726–731.
Tramposch, K.M., Chilton, F.H., Stanley, P.L., Franson, R.C, Havens, M.B., Nettleton, D.O., Davern, L.B., Darling, I.M. and Bonney, R.J. (1994). Inhibitor of phospholipase AZ blocks eicosanoid and platelet-activating factor biosynthesis and has topical anti-inflammatory activity. J. Pharmacol. Exp. Ther., 271, 852–859.
Rao, G.N., Lassegue, B., Alexander, R.W. And Griendlling, K.K. (1994). Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. Biochem. J., 299, 197–201.
Novakova, O., Drnkova, J., Kubista, V. Novak, F. (1994). Regulation of phospholipid degradation and biosynthesis in the heart by isoprenaline: effect of mepacrine. Physiol. Res., 43, 151–156.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lopes-Martins, R.A.B., Araújo, C.V., Estato, V., Moreira, S., Cordeiro, R.S.B., Tibiriçá, E.V. (1996). Platelet-Activating Factor. In: Nigam, S., Kunkel, G., Prescott, S.M. (eds) Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology, vol 416. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0179-8_36
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0179-8_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0181-1
Online ISBN: 978-1-4899-0179-8
eBook Packages: Springer Book Archive